Advertisement
Advertisement
KNSA
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
74.34
USDSponsored
-3.86
-4.94%
Jul 31, 15:59 UTC -4
Closed
After-Market
76.03
+1.69
+2.27%
KNSA Earnings Reports
Positive Surprise Ratio
KNSA beat 19 of 33 last estimates.
58%
Next Report
Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$261.79M
/$0.37
Implied change from Q2 26 (Revenue/ EPS)
+7.47%
/+23.33%
Implied change from Q3 25 (Revenue/ EPS)
+44.75%
/+60.87%
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares earnings per share and revenue
On Jul 28, 2026, KNSA reported earnings of 0.30 USD per share (EPS) for Q2 26, missing the estimate of 0.30 USD, resulting in a -1.54% surprise. Revenue reached 243.60 million, compared to an expected 229.97 million, with a 5.93% difference. The market reacted with a +25.03% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 0.37 USD, with revenue projected to reach 261.79 million USD, implying an increase of 23.33% EPS, and increase of 7.47% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alnylam Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.58
Actual
$1.21
Surprise
-23.70%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.38
Actual
$1.31
Surprise
-5.30%
Illumina Inc
Report Date
Jul 30, 2026 For Q1 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.02
Actual
$0.00
Surprise
-90.05%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
-$0.21
Surprise
+18.13%
Anavex Life Sciences
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.06
Surprise
+15.97%
Crescent Biopharma, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.74
Surprise
+8.74%
FAQ
What were Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares reported EPS of $0.30, missing estimates by -1.54%, and revenue of $243.60M, 5.93% above expectations.
How did the market react to Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Q2 2026 earnings?
The stock price moved up 25.03%, changed from $63.53 before the earnings release to $79.44 the day after.
When is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Oct 26, 2026.
What are the forecasts for Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's next earnings report?
Based on 6
analysts, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares is expected to report EPS of $0.37 and revenue of $261.79M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement